AUROPHARMA.NS Stock — Price, Charts & Analysis

Aurobindo Pharma Limited (AUROPHARMA.NS) has a trailing P/E of 25.12x and a forward P/E of 17.29x. This places AUROPHARMA.NS in a premium earnings multiple territory based on the valuation data currently available on Worldtickers.

AUROPHARMA.NS trades with 25.12x earnings on Worldtickers. Use valuation together with growth, balance sheet strength, and risk before deciding whether AUROPHARMA.NS looks overvalued or undervalued.

AUROPHARMA.NS's P/E of 25.12x should be judged against Healthcare peers, growth rate, margins, and balance sheet quality. A lower P/E may indicate value, while a higher P/E often means investors expect stronger future growth.

AUROPHARMA.NS's trailing EPS is ₹64.01 and forward EPS is ₹92.98. Reported earnings growth is 25.80%, which helps show current profit momentum.

EPS, or earnings per share, shows how much profit Aurobindo Pharma Limited generated for each share. AUROPHARMA.NS's trailing EPS is ₹64.01, and investors usually prefer EPS that is positive and growing over time.

Aurobindo Pharma Limited has a market cap of ₹925.21B, making AUROPHARMA.NS a large-cap stock based on the current market value shown on Worldtickers.

AUROPHARMA.NS's latest stock price on Worldtickers is ₹1,608.00. The latest move is -₹16.50 or -1.02%. Use the live quote, chart, volume, and 52-week range to judge the current trading context.

AUROPHARMA.NS's quote includes a latest price of ₹1,608.00. The market open is ₹1,631.00. Previous close is ₹1,624.50. The intraday range is ₹1,602.50 to ₹1,635.60.

AUROPHARMA.NS is down in the latest quote, with a move of -₹16.50 or -1.02%. To understand the reason, compare this move with news, earnings updates, analyst changes, sector performance, and market-wide direction.

AUROPHARMA.NS generated ₹349.35B in trailing revenue. Revenue growth is 16.30%, which helps show whether demand is expanding or slowing.

AUROPHARMA.NS's revenue growth is 16.30%, which is a strong demand signal in the latest available data. Investors usually compare revenue growth with margin trends and valuation to judge whether growth is profitable.

Yes, AUROPHARMA.NS shows positive profitability metrics in the latest data available on Worldtickers. Net income to common shareholders is ₹37.13B.

Gross margin is 58.85%. Margins show how efficiently Aurobindo Pharma Limited turns revenue into profit.

Aurobindo Pharma Limited carries ₹80.73B and holds ₹105.85B in cash.

AUROPHARMA.NS holds ₹105.85B on its balance sheet.

AUROPHARMA.NS's book value per share is ₹652.39.

Yes, Aurobindo Pharma Limited pays a dividend of ₹4.00 per share annually. The dividend yield is 24.00%. The payout ratio is 6.25%.

AUROPHARMA.NS's dividend yield is 24.00%. Its payout ratio is 6.25%, which helps judge dividend sustainability. Dividend investors usually prefer a reasonable yield, consistent cash flow, and a payout ratio that leaves room for reinvestment.

Worldtickers does not currently show a confirmed next ex-dividend date for AUROPHARMA.NS. The page does show dividend rate and yield when available, and investors should confirm record and payment dates through Aurobindo Pharma Limited's investor relations materials.

AUROPHARMA.NS's five-year average dividend yield is 65.00%. Use this alongside current yield, payout ratio, and cash flow to understand whether today's dividend looks high or low versus recent history.

Institutions hold 30.61% of AUROPHARMA.NS shares. Insiders hold 54.79% of shares. Ownership mix helps investors understand how much of Aurobindo Pharma Limited is held by professional investors and company insiders.

AUROPHARMA.NS has 575.38M shares outstanding. Float shares are 275.96M. Share count affects market cap, EPS, ownership percentages, and the impact of buybacks or dilution.

Insider activity can be useful context for AUROPHARMA.NS, especially when multiple executives buy shares with their own money. Insider selling is harder to interpret because executives may sell for taxes, diversification, or planned compensation reasons.

Forward EPS for AUROPHARMA.NS is ₹92.98. Earnings growth is 25.80%. Revenue growth is 16.30%. For earnings, investors usually watch EPS, revenue, margins, guidance, and management commentary.

AUROPHARMA.NS's trailing EPS is ₹64.01. Forward EPS is ₹92.98. Use the earnings section on the page to compare reported results, estimates, and trend changes when those datasets are available.

AUROPHARMA.NS is in the Healthcare sector. Its earnings multiple is 25.12x. Its latest displayed growth metric is 16.30%. Compare these figures with sector peers before deciding whether Aurobindo Pharma Limited is stronger or weaker than average.

AUROPHARMA.NS trades at ₹1,608.00. The stock trades at 25.12x earnings. Whether to invest depends on your risk tolerance, time horizon, diversification, and view of Aurobindo Pharma Limited's fundamentals.

AUROPHARMA.NS risks include company execution, valuation, competition in Healthcare, interest rates, and broad market volatility. Beta is 0.02, which helps estimate market sensitivity. No single stock should be evaluated without portfolio context.

AUROPHARMA.NS should be compared with companies in Drug Manufacturers - Specialty & Generic. Its earnings multiple is 25.12x. Useful comparison points include revenue growth, margins, debt, cash flow, valuation, analyst targets, and price momentum.

Aurobindo Pharma Limited (AUROPHARMA.NS) operates in Healthcare, specifically Drug Manufacturers - Specialty & Generic. Aurobindo Pharma Limited, a pharmaceutical company, develops, manufactures, and commercializes generic pharmaceuticals in India, the United States, Europe, and internationally. The company manufactures a range of finished formulation products in various forms, such as oral solids, liquids, injectables for generic pharmaceuticals, branded specialty pharmaceuticals, and active pharmaceutical ingredients for CNS, anti-retroviral, cardiovascular, antibiotics, gastroenterology, anti-diabetics, and anti-allergic therapeu

AUROPHARMA.NS trades on NSE. Exchange context matters because trading hours, liquidity, currency, and settlement rules can differ across markets.

AUROPHARMA.NS stock is priced in INR on Worldtickers. Currency matters for international investors because exchange-rate moves can affect local-currency returns.

Aurobindo Pharma Limited's official website listed on Worldtickers is www.aurobindo.com. Investor relations pages are useful for earnings releases, annual reports, filings, and shareholder presentations.

Aurobindo Pharma Limited employs about 29.21K people based on the latest company profile data available on Worldtickers. Workforce size helps investors understand company scale and operating complexity.

Aurobindo Pharma Limited is headquartered in Hyderabad, India. Headquarters location can matter for currency, regulation, tax, labor market, and regional economic exposure.

AUROPHARMA.NS is in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Sector context helps investors compare valuation, growth, margins, and risk against similar companies.

AUROPHARMA.NS has traded between ₹1,016.10 and ₹1,682.40 over the past 52 weeks. At ₹1,608.00, it is 4.42% below the high and 58.25% above the low. The 52-week range helps gauge long-term price momentum.

AUROPHARMA.NS is above both its 50-day and 200-day moving averages, which is a common uptrend signal. Its 50-day moving average is ₹1,565.54 and its 200-day moving average is ₹1,352.17.

AUROPHARMA.NS's RSI is 53.97. Readings below 30 are commonly viewed as oversold, above 70 as overbought, and the current reading suggests a neutral momentum setup.

AUROPHARMA.NS's latest RSI reading is 53.97, which points to neutral momentum today. Traders usually confirm RSI with volume, trend, and nearby support or resistance.

Key support for AUROPHARMA.NS is near ₹1,512.00. Key resistance is near ₹1,682.40. Breaks above resistance or below support can change the short-term technical setup.

AUROPHARMA.NS's nearest reported support level is ₹1,512.00. A clean break below support can weaken the short-term setup, while repeated bounces can show demand.

AUROPHARMA.NS's nearest reported resistance level is ₹1,682.40. A breakout above resistance can improve momentum, especially when volume confirms the move.

AUROPHARMA.NS trades about 1.25M shares daily on average. The latest displayed volume is 805.52K shares. Volume helps show liquidity and whether trading interest is unusually high or low.

AUROPHARMA.NS's MACD is -3.86, which is a negative momentum reading. MACD should be reviewed with price trend, moving averages, RSI, volume, and support or resistance levels.

AUROPHARMA.NS is above both its 50-day and 200-day moving averages, which is a common uptrend signal. RSI is 53.97 (neutral). MACD is bearish. Nearest support is around ₹1,512.00. Resistance is around ₹1,682.40. A buy decision should also consider valuation, earnings quality, risk tolerance, and position sizing.

MA20 is ₹1,611.56 (0.60% from price). MA50 is ₹1,565.54 (3.56% from price). MA200 is ₹1,352.17 (19.90% from price). The moving-average stack helps separate short-term momentum from long-term trend risk.

The server report currently confirms daily moving-average levels rather than a separate EMA-only value. AUROPHARMA.NS's MA20 is ₹1,611.56. MA50 is ₹1,565.54. For EMA-specific overlays, use the live chart indicators and compare EMA direction with RSI, MACD, volume, support, and resistance.

AUROPHARMA.NS's pivot is near ₹1,615.37. Support is near ₹1,512.00. Resistance is near ₹1,682.40. Price holding above pivot can support a constructive setup, while rejection near resistance can cap momentum.

The next lower support zone for AUROPHARMA.NS is near ₹1,586.85. The next upper resistance zone is near ₹1,677.15. These levels help define risk and possible follow-through zones after a breakout or breakdown.

AUROPHARMA.NS's Bollinger range is roughly ₹1,536.76 to ₹1,686.36. Band width is near 9.28%. Price near the upper band can show stretched upside momentum, while price near the lower band can show downside pressure or a possible mean-reversion zone.

AUROPHARMA.NS's ATR-based typical daily range is about 2.21%. ATR helps size risk because wider ranges usually require wider stops or smaller position sizes.

Latest volume is 805.52K shares. Average volume is about 1.25M shares. Breakouts with rising relative volume are usually more reliable than moves on light participation.

AUROPHARMA.NS's all-time high shown on Worldtickers is ₹1,682.40. Its all-time low is ₹2.35. All-time levels provide long-range context, but recent fundamentals and market conditions matter more for current decisions.

AUROPHARMA.NS has a beta of 0.02, meaning it has historically been less volatile than the broad market. Beta is useful for judging how much a stock may move during broad market swings.